Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.
Pfizer announced that the company’s Phase III RESET clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the study’s primary and key secondary efficacy endpoints.
Amicus Therapeutics announced positive interim results from the company’s CLN6 Batten disease gene therapy program.
Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.
Zogenix plans to resubmit a New Drug Application for Fintepla (fenfluramine) to treat seizures associated with Dravet syndrome.
Myovant is preparing to seek regulatory approval for the company’s once-daily relugolix combination therapy for the treatment of uterine fibroids following positive Phase III results that showed a 71.2 percent response rate in patients.
GlaxoSmithKline, Pfizer and Shinogi’s joint venture ViiV Healthcare said the Phase III BRIGHTE study hit 96-week endpoints in heavily treatment-experienced adults with HIV-1 infection.
Acadia Pharmaceuticals Inc.’s add-on treatment pimavanserin for schizophrenia failed to meet the main goal in a late-stage study.
Shares of Israel-based Intec Pharma Ltd. were down nearly 82 percent after the company announced that the Phase III Parkinson’s disease therapy Accordion Pill failed to demonstrate statistical superiority to treatment with Sinemet, a combination of carbidopa and levodopa.
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.